Purpose: Montelukast, a selective cysteinyl leukotriene D4-receptor antagonist, is used in the treatment of asthma. In a rat model, our aim was to investigate the e ects of montelukast, alone or in combination with topical antibiotics, on local burn wound healing.
Burn wounds constitute a signi cant proportion of emergency service admissions. Although most epidermal burn wounds heal without intervention, severe burn wounds need medical treatment. Treatment of burn wounds aims to decrease the infection and in ammation. Topical antimicrobial agents containing bacitracin, neomycin, silver sulfadiazine and mafenide have been used clinically to eliminate infections common in local burn wounds [1] . In burn cases, in ammatory response is associated with local and systematic tissue damage and lipid peroxidation [2, 3] , as re ected by an increase in macrophage activity and production of pro-in ammatory mediators and evenincreased levels of interleukin 1 beta (IL-1β), interleukin 6 (IL-6), tumor necrosis factor-alpha (TNF-α), tumor growth factor beta (TGF-β), leukotriene B4 (LTB4) and lipoxygenase metabolites [4] [5] [6] . is suggests that pro-in ammatory cascade plays a role in a number of post-burn complications [7] .
Leukotrienes, produced from arachidonic acid by the enzyme 5-lipoxygenase, promotes permeability and is chemotactic. LTB4 are important modulators of various neutrophiles functions including adherence and chemotaxis [8] . Leukotriene C4 (LTC 4 ), leukotriene D4 (LTD 4 ), leukotriene E4 (LTE 4 ) (cysteinyl leukotrienes) are released mainly by eosinophils, mast cells, monocytes, macrophages and are elevated in response to in ammation [9] [10] [11] .
Montelukast is a new anti-in ammatory medicine used in the treatment of asthma. It is a potent and selective antagonist of the cysteinyl leukotriene 1 (cys-LT1) receptor (LTD4 receptor) and inhibits cys-LT [12] . Montelukast also prevents multiple organ dysfunction and local in ammation, and suppresses the release of proin ammatory mediators and the in ltration of neutrophiles [2] . e anti-oxidant and anti-in ammatory e ects of montelukast have also been used clincally to treat burn-induced gut injury [13] ; however, few studies dealing with the e ects of montelukast on skin burn wound healing are available. e objective of this study was to investigate the effects of montelukast, alone or in combination with topical antibiotics, on the local burn wound healing in a rat model.
Methods
A total of 32 males, Sprague-Dawley rats, weighing 300-325 g, were provided by the Experimental Animal Laboratory of Inonu University. Prior to the trial, rats were housed in sterilized polypropylene rat cages, in 12-h light-dark cycle, at an ambient temperature of 21°C. Food and drinking water were given . Experiments were performed based on the animal ethics guidelines of Institutional Animals Ethics Committee.
Four burned areas and three unburned areas adjacent to the burned areas were generated [14] . In this model, a brass comb with four 10×20 mm rectangular prongs separated by three 5 mm notches, which produces four distinctive burns sites separated by three interspaces of unburned skin, was used. All the rats were anesthetised intraperitoneally with a mixture of 80 mg/kg ketamine and 5 mg/kg xylazine. e backs of the rats were shaved, the brass comb was heated in a boiling water bath for 5 min, and then the brass comb was contacted to the shaved area of rat dorsum for 30 s without pressure. A er reheating the brass comb, it was contacted to the other adjacent shaved region of the dorsum. Hence, two comb burns on either side of each rat were formed ( Figure 1 ). All the rats were resuscitated with physiological saline solution (10 ml/kg, subcutaneously). e rats were randomly allocated to four groups of eight: Group 1, rats were le to secondary healing without treatment; Group 2, a dose of 10 mg/kg montelukast was given by gastric gavage once a day for 10 days; Group 3, rats were treated with topical antibiotic (bacitracin neomycin sulphate); and Group 4, topical antibiotic was applied and montelukast (10 mg/kg) was given by gastric gavage once a day for 10 days. Physiological saline solution was given by gastric gavage to Groups 1 and 3 to provide standardization. Healing of a burn wound was investigated through stages 1 and 2: : stage 1, in ammation phase (2-4 days); stage 2, proliferation phase (granulation tissue generation and reepithelialization, 3-20 days) [15, 16] . Skin biopsies were taken on the 3 rd , 10 th , 14 th , 20 th days following Turtay et al. Montelukast improves burn wound healing burn development. On these days, skin biopsy specimens of the rats were taken from the same anatomical locations to include the burn wound tissue. One rat from each group died before the 20 th day. All rats were sacri ced on day 20. Biopsy specimens were investigated histopathologically.
Biopsy samples were xed in 10% formalin and embedded in para n blocks, Sections (5 μm thick) were stained with hematoxylin-eosin (H&E) and examined using light microscopy. On the 3 rd day subepithelial neutrophil were counted and on the 10 th , 14 th , and 20 th days reepithelialization, angiogenesis, edema, broblast and macrophage were evaluated. Subepithelial neutrophil, angiogenesis, edema, and broblast and macrophage density were evaluated in accordance with the percentage of the densities in a 40X magni ed dissected area of the burn region.
e scoring of the parameters mentioned above was determined as absent (0) when it was between 0-10%; mild (1) when it was between 10-40 %; moderate (2) when it was between 40-70% and severe (3) when it was between 70-100%. e length of reepithelialization was evaluated in 40X magni ed sections. e scoring was determined as absent (0) when reepithelialization was not present; mild (1) when reepithelialization was up to 1/3 of the burn area; moderate (2) when reepithelialization was up to 2/3; severe (3) when reepithelialization was more than 2/3. e investigator conducting histopathological examination was blinded and allocation concealment was maintained using sealed envelopes. 
Results
In the epidermis, skin appendage homogeneity of the dermis con rmed the formation of burn wounds in all groups. Table 1 summarizes histopathological responses in all experimental groups over the course of 20 days. In the in ammation phase, neutrophil in ltration was severe in the control group (group 1), mild in montelukast group (group 2) and pomade group (group 3) and absent in the montelukast+ pomade group (group 4) (Figures 2 and 3) . Montelukast, pomade and montelukast+pomade groups were signi cantly di erent from control group (p<0.05).
In the proliferation phase, the length of reepithelialization, broblast proliferation, edema, angiogenesis and macrophage in ltration were evaluated. Reepithelialization in the pomade and montelukast+pomade groups on the 10 th day was improved, in comparison with the control and montelukast groups (p<0.05); however,reepithelialization was not observed in the control and montelukast groups. On the 14 th and 20 th days, montelukast, pomade and montelukast+pomade groups were signi cantly di erent from the control group (p<0.05). No reepithelialization was observed in the control group until the 20 th day.
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Clin In E415 (0) when it was between when it was between 70-100%. t (0) when reepithelialization was zation was up to 2/3; severe (3) wh antly di ereutrophil, agni ed n 0-10%; e length of not present; hen reepiAngiogenesis in the montelukast group was lower than in the control group on the 20 th day (p<0.05). Angiogenesis in the pomade group was also lower than in the control group on the 10 th , 14 th and 20 th days (p<0.05). Angiogenesis in the montelukast+pomade group was lower than in the control group on the 10 th , 14 th and 20 th days (p<0.05) (Figures 4 and 5 ). Angiogenesis in the montelukast group was greater than in the pomade group on the 10 th day (p<0.05). Angiogenesis in the montelukast+pomade group was lower than in the montelukast and pomade groups on the 10 th day (p<0.05).
Edema in the montelukast group lower than in the control group on the 14 th and 20 th days (p<0.05). Edema in the pomade group was also lower than in the control group on the 14 th and 20 th days (p<0.05). Edema in the montelukast+po-made group was lower than in the control group on the 14 th and 20 th days (p<0.05). Edema in the montelukast+pomade group was lower in the montelukast and pomade groups on the 10 th day (p<0.05).
Fibroblast proliferation in the montelukast group was lower than in the control group on the 20 th day (p<0.05). Fibroblast proliferation in the pomade group was lower than in the control group on the 14 th and 20 th days (p<0.05). Fibroblast proliferation in the montelukast+pomade group was lower than in the control group on the 10 th , 14 th and 20 th days (p<0.05). Fibroblast proliferation in the montelukast+pomade group was lower than in the montelukast and pomade groups on the 10 th day (p<0.05).
Macrophage in ltration in the montelukast group was lower than in the control group on the 20 th day (p<0.05). Macrophage in ltration in the pomade group was lower than in the control group on the 14 th and 20 th days (p<0.05). Macrophage in ltration in the montelukast+pomade group was lower than in the control group on the 10 th , 14 th and 20 th days (p<0.05) (Figures 6 and 7) . Macrophage in ltration in the montelukast group was lower than in the pomade group on the 10 th day (p<0.05). Macrophage in ltration in the montelukast+pomade group was lower than in the montelukast group on the 10 th day (p<0.05).
While angiogenesis, broblast proliferation, edema and macrophage in ltration were moderate and severe in group 1 on the 14 th and 20 th days (Figure 8 ), they were mild in group 2, group 3 and group 4 on the 14 th and 20 th days ( Figure 9 ).
Figures 10-12 depict the graphics of each variable assessed over time in montelukast, pomade, montelukast+pomade groups.
Discussion
Healing of burn wounds is a complicated process that starts with the in ltration of in ammatory cell such as neutrophils, lymphocytes and macrophages. ese in ammatory cells are activated by factors released in the burn process. Once activated, in ammatory cells attempt to eliminate the cause of the damage by producing mediators such as cytokines (TNF-α, IL-1, IL-6 etc) and some growth factors ( broblast growth factor (FGF), platelet-derived growth factor (PDGF) and epidermal growth factor (EGF)). e cytokines and growth factors start regeneration of epidermis destroyed as a result of the burn, and trigger broblast proliferation on the damaged dermis. Other processes in burn healing are angiogenesis and generation of granulation tissue, synthesis of extracellular matrix Turtay et al. Montelukast improves burn wound healing proteins, storage of collagen and remodelling. e in ammatory response is required to drain damaged tissue debris. Lysosomal enzymes in neutrophiles and macrophages, reactive oxygen metabolites, products of arachidonic acids metabolism like leukotrienes and prostaglandins also play roles in the in ammatory process. As these products also have the ability to cause endothelial injury and tissue damage, they may intensify the damage on the injured area [17] [18] [19] .
In order to minimize the damage of the defence system, which has a capacity to cause tissue damage, anti-in ammatory lipoxin, produced from arachidonic acid, as well as TGF-β and TNF are kept under control by mechanisms that inhibit macrophage release. Anti-in ammatory drugs aim at healing by reducing in ammation [2, 4, 14, [20] [21] [22] .
Neutrophils are the primary cells of the in ammation phase and accumulate in on the damaged tissue within the rst 24 hours. From the 3 rd day, granulation tissue starts to form and macrophage in ltration begins. On the 5 th day, neovascularisation (angiogenesis) has peaked and reepithelialization starts. From the 2 nd week, in ltration of in ammatory cells and increased vascularity declines substantially and collagen accumulation starts. A er the 2 nd week, in the in ammation and proliferation phase, the macroscopic burn area appears erythematous, turns white a er the end of angiogenesis, and scar tissue forms by the end of the 1 st month [15, 16] .
Although the adverse e ects of montelukast, such as asthenia, fatigue, headache, hepatitis and Churg-Strauss syndrome, are known, it is still routinely used in the treatment of asthma [23] [24] [25] . Montelukast likely exerts the antiin ammatory e ect in burn injury through suppression of a Turtay et al. Montelukast improves burn wound healing variety of proin ammatory mediators produced by the leukocytes and macrophages [13] . It has been reported that digestive system injuries, that frequently occur in the setting of burns, associate with leukotrienes production and that patients with severe injuries have increased LTE 4 excretion in their urine in comparison with healthy individuals [13, 26] . Consequently, leukotriene receptor blockers may be e ective in treating burn injuries. In a study carried out on rabbits, the researchers determined that S 872419 A, which is a speci c receptor antagonist of peptide leukotrienes, boosted healing of the chemical burn generated in the eye and concluded that other nonsteroidal drugs should improve the anti-in ammatory therapy of the chemically-burned eye [27] . Due to its anti-in ammatory and anti-oxidant e ects, montelukast might be useful in the treatment of burn-induced skin and gut injury [2, 13] ; however, in the research carried out by Sener and Kabasakal et ,montelukast is only compared with saline for the treatment of burn injuries [2, 13] . Our research compares montelukast with topical antibiotics. In this respect, it is di erent from the other reported studies.
Burns are susceptible to infection,which is one of the factors that disrupt the healing of these wounds. For this reason, topical antibiotics [1] or antiseptic treatment may be required. Even antiseptic therapy, with a polylacticacid-acetic acid matrix, has an equivalent e ectiveness to silver sulfadiazine in the treatment of second and third degree burns [28] .
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Clin In E419 In this study, in group 2, montelukast administration caused signi cant reduction in the density of neutrophil leukocytes on the 3 rd day -and to a similar extent as that seen with the application of pomade (group 3). e anti-in ammatory e ect was observed to be maximum in group 4; where montelukast and topical pomade were administered together. In group 4, hardly any neutrophil leukocytes were observed in the tissue samples. In the proliferation phase, reepithelialization existed as of the 10 th day in the two groups where pomade was applied; both solely and in combination with montelukast (groups 3 and 4, respectively) and reepithelialization length increased as the days passed. It was observed that group 4, where montelukast was administered in combination with application of pomade, had the maximum reepithelialization length. No reepithelialization occurred in group 2 on the 10 th day, where montelukast was administered without pomade. Although montelukast provided an anti-in ammatory e ect, it could not induce reepithelialization. Consistent with the healing process of the burn wound, as of 10 th day,angiogenesis, edema, macrophage in ltration, broblast proliferation decreased and collagen production increased. In group 4, where montelukast was administered in combination with application of pomade, these parameters decreased and collagen production increased further in comparison with the groups where montelukast and pomade were administered separately (groups 2 and 3, respectively). us, although montelukast is not superior to the topical antibiotic pomade routinely used for the treatment of burn injuries, it did show improved outcomes relative to no treatment. e best outcomes were achieved when montelukast was combined with local antibiotic pomade.
ere may be two reasons for this. e rst is that a stronger e ect may be generated by the combination of independent e ects of montelukast and the topical antibiotic. e second is that montelukast may decrease the in ammation and oxidation caused by the burn injury and help the topical pomade to show its e ects better.
Conclusion
We conclude that montelukast is e ective in promoting burn wound healing. e e ect becomes more signi cant when combined with the application of a topical antibiotic in the early stage of burn wound healing.
